Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluation of toxicity: statistical considerations

J Herson

    Cancer Treatment Reports
    |February 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    This study evaluates statistical methods for assessing toxicity in phase III cancer trials. It focuses on analyzing unacceptable toxicity frequency and addresses key questions about its necessity and impact on treatment outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity.

    Proceedings of the National Academy of Sciences of the United States of America·2000
    Same author

    Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis.

    Journal of the American Society of Nephrology : JASN·1993
    Same author

    Data monitoring boards in the pharmaceutical industry.

    Statistics in medicine·1993
    Same author

    Comparative evaluation of urographic contrast media, inulin, and 99mTc-DTPA clearance methods for determination of glomerular filtration rate in clinical transplantation.

    Transplantation·1989
    Same author

    A retrospective analysis of long-term renal allograft function associated with cyclosporine-prednisone immunosuppressive therapy.

    Transplantation proceedings·1988
    Same author

    Projection from previous studies: a Bayesian and frequentist compromise.

    Controlled clinical trials·1987
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Area of Science:

    • Biostatistics
    • Clinical Trials
    • Oncology

    Background:

    • Evaluating treatment toxicity is crucial in oncology clinical trials.
    • Phase III trials require robust statistical methods for toxicity assessment.

    Purpose of the Study:

    • To present statistical considerations for evaluating toxicity in phase III oncology trials.
    • To analyze the frequency of unacceptable toxicity within treatment periods and prognostic groups.

    Main Methods:

    • Concentrated analysis on toxicity frequency by treatment period.
    • Categorized toxicity questions into general (descriptive, assessment, etiology) and specific (study design-related).
    • Discussed life-table methods, toxicity index creation, and approaches to the necessity of toxicity.

    Related Experiment Videos

    Main Results:

    • Identified general and specific toxicity questions relevant to trial design and analysis.
    • Highlighted the application of life-table methods and toxicity indices.
    • Evaluated approaches to the fundamental question of toxicity necessity in cancer therapy.

    Conclusions:

    • Statistical considerations are vital for accurate toxicity evaluation in phase III oncology trials.
    • The study provides frameworks for addressing toxicity assessment, etiology, and its role in treatment decisions.
    • Emphasized the importance of evaluating late effects of therapy.